Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, and Cancer Treatment and Pharmacology.
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.
Breast cancer patients' preferences for digital supportive care content: Preliminary findings and future directions.
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.
Supplementary Data 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Supplementary Table 4 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Supplementary Table 1 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Supplementary Tables 9-17 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Figure 2 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Table 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Data from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Supplementary Tables 5-8 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Data from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Figure 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Supplementary Table 18 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Figure 3 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Supplementary Table 2 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Figure 5 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Supplementary Figures from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Supplementary Table 3 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Figure 4 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
Overall survival with abemaciclib in early breast cancer
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.
Supplementary Figure S6 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S3 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
Supplementary Table S3 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S7 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table S1 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S4 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer